2212 related articles for article (PubMed ID: 18783735)
41. Relative importance of PSA in prostate cancer treatment.
Unger HA; Kane RD; Fox KM; Gandhi S; Alzola C; Lamerato L; Newling D; Kumar S
Urol Oncol; 2005; 23(4):238-45. PubMed ID: 16018938
[TBL] [Abstract][Full Text] [Related]
42. Early intervention or expectant management for prostate cancer. The Prostate Cancer Intervention Versus Observation Trial (PIVOT): a randomized trial comparing radical prostatectomy with expectant management for the treatment of clinically localized prostate cancer.
Wilt TJ; Brawer MK
Semin Urol; 1995 May; 13(2):130-6. PubMed ID: 7638470
[No Abstract] [Full Text] [Related]
43. Primary treatment choices for men with clinically localized prostate carcinoma detected by screening.
Yan Y; Carvalhal GF; Catalona WJ; Young JD
Cancer; 2000 Mar; 88(5):1122-30. PubMed ID: 10699903
[TBL] [Abstract][Full Text] [Related]
44. Salvage radical prostatectomy for radiorecurrent prostate cancer: morbidity revisited.
Vaidya A; Soloway MS
J Urol; 2000 Dec; 164(6):1998-2001. PubMed ID: 11061900
[TBL] [Abstract][Full Text] [Related]
45. Validity of prostate-specific antigen as a tumour marker in men with prostate cancer managed by watchful-waiting: correlation with findings at serial endorectal magnetic resonance imaging and spectroscopic imaging.
Coakley FV; Chen I; Qayyum A; Westphalen AC; Carroll PR; Hricak H; Chen MH; Kurhanewicz J
BJU Int; 2007 Jan; 99(1):41-5. PubMed ID: 17227490
[TBL] [Abstract][Full Text] [Related]
46. Mental health in men treated for early stage prostate carcinoma: a posttreatment, longitudinal quality of life analysis from the Cancer of the Prostate Strategic Urologic Research Endeavor.
Litwin MS; Lubeck DP; Spitalny GM; Henning JM; Carroll PR
Cancer; 2002 Jul; 95(1):54-60. PubMed ID: 12115317
[TBL] [Abstract][Full Text] [Related]
47. Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors.
D'Amico AV; Chen MH; Catalona WJ; Sun L; Roehl KA; Moul JW
Cancer; 2007 Jul; 110(1):56-61. PubMed ID: 17530618
[TBL] [Abstract][Full Text] [Related]
48. Conventional treatments of localized prostate cancer.
Zerbib M; Zelefsky MJ; Higano CS; Carroll PR
Urology; 2008 Dec; 72(6 Suppl):S25-35. PubMed ID: 19095125
[TBL] [Abstract][Full Text] [Related]
49. Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance.
Roemeling S; Roobol MJ; Postma R; Gosselaar C; van der Kwast TH; Bangma CH; Schröder FH
Eur Urol; 2006 Sep; 50(3):475-82. PubMed ID: 16713065
[TBL] [Abstract][Full Text] [Related]
50. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
Nieder AM; Porter MP; Soloway MS
J Urol; 2008 Nov; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517
[TBL] [Abstract][Full Text] [Related]
51. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
[TBL] [Abstract][Full Text] [Related]
52. Relapse after radical prostatectomy correlates with preoperative PSA velocity and tumor volume: results from a screening population.
Berger AP; Deibl M; Strasak A; Bektic J; Pelzer A; Steiner H; Spranger R; Fritsche G; Bartsch G; Horninger W
Urology; 2006 Nov; 68(5):1067-71. PubMed ID: 17095070
[TBL] [Abstract][Full Text] [Related]
53. [Surgical and medical treatment for localized prostate cancer].
Kawai K
Gan To Kagaku Ryoho; 2007 Jul; 34(7):1002-5. PubMed ID: 17637535
[TBL] [Abstract][Full Text] [Related]
54. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
Pinsky PF; Andriole G; Crawford ED; Chia D; Kramer BS; Grubb R; Greenlee R; Gohagan JK
Cancer; 2007 Apr; 109(8):1689-95. PubMed ID: 17330856
[TBL] [Abstract][Full Text] [Related]
55. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods.
Yossepowitch O; Eggener SE; Bianco FJ; Carver BS; Serio A; Scardino PT; Eastham JA
J Urol; 2007 Aug; 178(2):493-9; discussion 499. PubMed ID: 17561152
[TBL] [Abstract][Full Text] [Related]
56. Evaluation of changes in prostate specific antigen in clinically localized prostate cancer managed without initial therapy.
Gerber GS; Gornik HL; Goldfischer ER; Chodak GW; Rukstalis DB
J Urol; 1998 Apr; 159(4):1243-6. PubMed ID: 9507845
[TBL] [Abstract][Full Text] [Related]
57. The Prostate Cancer Intervention Versus Observation Trial (PIVOT).
Wilt TJ; Brawer MK
Oncology (Williston Park); 1997 Aug; 11(8):1133-9; discussion 1139-40, 1143. PubMed ID: 9268976
[TBL] [Abstract][Full Text] [Related]
58. Baseline prostate-specific antigen level and risk of prostate cancer and prostate-specific mortality: diagnosis is dependent on the intensity of investigation.
Connolly D; Black A; Gavin A; Keane PF; Murray LJ
Cancer Epidemiol Biomarkers Prev; 2008 Feb; 17(2):271-8. PubMed ID: 18250343
[TBL] [Abstract][Full Text] [Related]
59. Prostate-specific antigen levels as a predictor of lethal prostate cancer.
Fall K; Garmo H; Andrén O; Bill-Axelson A; Adolfsson J; Adami HO; Johansson JE; Holmberg L;
J Natl Cancer Inst; 2007 Apr; 99(7):526-32. PubMed ID: 17405997
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
